Bowman-Birk Inhibitor Concentrate in Healthy Men

Inclusion criteria

* Healthy male participant recruited from the Philadelphia, Pennsylvania metropolitan area * ECOG performance status 0-2 * WBC ≥ 3,000/uL * Differential (i.e., neutrophils, lymphocytes, monocytes, bands, eosinophils, and basophils) normal * Platelet count normal * Hemoglobin normal * Hematocrit normal * RBC normal * Creatinine normal * Bilirubin normal * ALT and AST normal * Amylase and lipase normal * Glucose normal * Cholesterol normal * Triglycerides normal * Non-smoker * Former smokers are eligible provided they have not smoked within the past 3 months * Within 15% of ideal body weight based on standard weight tables * No vegetarians or individuals who normally ingest large amounts of soy products, defined as two or more servings of tofu, soy milk, or other primarily soy-based food per day * No prior allergy or adverse reaction to soybeans * No diagnosis of cancer within the past 5 years except nonmelanoma skin cancer * No prior diagnosis of pancreatitis, pancreatic carcinoma, pancreatic adenoma, diabetes mellitus, obstruction of pancreatic ducts, or amyloidosis * No history of heart disease * EKG normal (normal variants allowed) * No evidence of psychiatric problems * No history of excessive alcohol consumption (i.e., an average of \> 2 alcoholic beverages per day) * No alcohol consumption within the past 3 days * No history of any medical condition that could influence gastrointestinal uptake of the drug * No history of chronic medical condition * No evidence of another life-threatening disease * More than 12 months since prior chemotherapy * More than 1 month since prior experimental drugs * More than 2 weeks since prior and no concurrent regular use (i.e., \> 3 times/week) of nonsteroidal anti-inflammatory drugs (NSAIDs) * More than 2 weeks since prior and no concurrent multivitamin tablets (or other vitamin supplements) of \> 2 per day